Clinical Trials Browser

Interventional × Squamous Cell Carcinoma of Head and Neck × cemiplimab × Clear all

NCT06980038 2026-03-19

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

NCT06855212 2026-02-20

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04862650 2026-02-10

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06022029 2025-12-24

ON-5001

Phase 1 Recruiting

BreastDermatologicGenitourinaryGynecologicHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Bites and Stings, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma in Situ, Uterine Cervical Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Skin Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Triple Negative Breast Neoplasms

NCT06769698 2025-12-16

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT04722523 2025-09-23

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Phase 1 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04305795 2025-06-19

An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Phase 1/2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT03916627 2025-04-11

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Phase 2 Active not recruiting

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular

NCT04291105 2025-03-26

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Phase 2 Recruiting

DermatologicGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Colonic Neoplasms, Melanoma

NCT04465487 2025-02-24

Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies

Phase 1 Terminated

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis

NCT04398524 2024-01-16

A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck

NCT03669718 2023-12-29

A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck

NCT05094804 2023-11-02

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Phase 1/2 Unknown

DermatologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Leiomyosarcoma, Liposarcoma, Melanoma, Neoplasm Metastasis, Neoplasms

NCT04831450 2022-08-04

Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 2 Withdrawn

Squamous Cell Carcinoma of Head and Neck